Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusTherapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsMelanoma immunotherapy using mature DCs expressing the constitutive proteasome
/in Dendritic Cells, International Publications, Malignant MelanomaActive immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International PublicationsA Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerBiochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
/in Dendritic Cells, International Publications, Malignant MelanomaImmune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients
/in Dendritic Cells, International PublicationsEffect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients.
/in Dendritic Cells, International Publications, Malignant MelanomaSurvival in metastatic Ewing sarcoma (EWS) and rhabdomyosarcoma (RMS) following consolidation immunotherapy with autologous lymphocyte infusion, dendritic cell vaccines ± CYT107 (rhIL-7).
/in Dendritic Cells, Hypernephroma, International Publications, Soft Tissue Sarcoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer